FDA to CytoDyn: Those 2 Covid trials you keep touting both failed on all endpoints and your subgroup analysis doesn't help. Are we clear now?
As a matter of official policy, the FDA doesn’t comment about unapproved drugs and the data gathered to back them.
As an unofficial policy, though, the agency can still be provoked by a seemingly unending stream of promotional releases to call a company out for a complete and utter failure.
So it was today with CytoDyn, a biotech company that has a habit of blasting statements out about their drug leronlimab, which has been touted as a potential treatment for Covid-19.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.